Autor: "Lickliter JD" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
Autorzy:: Lickliter JD
Gan HK
Voskoboynik M
Arulananda S
Gao B
Nagrial A
Grimison P
Harrison M
Zou J
Zhang L
Luo S
Lahn M
Kallender H
Mannucci A
Somma C
Woods K
Behren A
Fernandez-Penas P
Millward M
Meniawy T; Pokaż więcej
Temat:: pd-1
monoclonal antibody
first-in-human dose study
cancer
reactive cutaneous capillary endothelial proliferation
Therapeutics. Pharmacology
RM1-950
Źródło:: Drug Design, Development and Therapy, Vol Volume 14, Pp 1177-1189 (2020)
Opis pliku:: electronic resource
Relacje:: https://www.dovepress.com/a-first-in-human-dose-finding-study-of-camrelizumab-in-patients-with-a-peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881
Dostęp URL:: https://doaj.org/article/dd96faf93e9d478a820d20188acc20e1 Link otwiera się w nowym oknie

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 2.

Tytuł:: Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation
Autorzy:: Lickliter, JD
McGlave, PB
DeFor, TE
Miller, JS
Ramsay, NK
Verfaillie, CM
Burns, LJ
Wagner, JE
Eastlund, T
Dusenbery, K
Weisdorf, DJ; Pokaż więcej
Źródło:: Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 26(7):723-728

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Informacja:: Dostęp do tej pozycji wymaga zalogowania się.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 5.

Tytuł:: A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases.
Autorzy:: Chen MC; PureTech Health, Boston, Massachusetts, USA.
Korth CC; PureTech Health, Boston, Massachusetts, USA.
Harnett MD; PureTech Health, Boston, Massachusetts, USA.
Elenko E; PureTech Health, Boston, Massachusetts, USA.
Lickliter JD; Nucleus Network, Melbourne, Australia.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Feb; Vol. 11 (2), pp. 220-234. Date of Electronic Publication: 2021 Nov 15.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Lung Diseases, Interstitial*/chemically induced
Lung Diseases, Interstitial*/drug therapy
Pyridones*/adverse effects
Deuterium/therapeutic use ; Dose-Response Relationship, Drug ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial.
Autorzy:: Depelsenaire ACI; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.
Witham K; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.
Veitch M; The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia.
Wells JW; The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia.
Anderson CD; Department of Clinical and Experimental Medicine, Linkoping University, Linköping, Sweden.
Lickliter JD; Nucleus Network Pty Ltd, Melbourne, Victoria Australia.
Rockman S; Seqirus Pty Ltd, Parkville, Victoria, Australia.; Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Bodle J; Seqirus Pty Ltd, Parkville, Victoria, Australia.
Treasure P; Peter Treasure Statistical Services Ltd, Kings Lynn, United Kingdom.
Hickling J; Working in Tandem Ltd, Cambridge, United Kingdom.
Fernando GJP; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.; The University of Queensland, School of Chemistry & Molecular Biosciences, Faculty of Science, Brisbane, Queensland, Australia.
Forster AH; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Jul 30; Vol. 16 (7), pp. e0255282. Date of Electronic Publication: 2021 Jul 30 (Print Publication: 2021).
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Drug Delivery Systems*
CD4-Positive T-Lymphocytes/*immunology
CD8-Positive T-Lymphocytes/*immunology
Immunity, Cellular/*drug effects
Influenza A Virus, H1N1 Subtype/*immunology
Influenza Vaccines/*administration & dosage
Skin/*immunology
Adult ; Antigens, CD/immunology ; Female ; Humans ; Influenza Vaccines/immunology ; Influenza, Human/immunology ; Influenza, Human/prevention & control ; Male ; Middle Aged ; Time Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Autorzy:: Yang J; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Lickliter JD; Nucleus Network, Melbourne, Victoria, Australia.
Hillson JL; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Means GD; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Sanderson RJ; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Carley K; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Tercero A; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Manjarrez KL; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Wiley JR; Alpine Immune Sciences, Inc., Seattle, Washington, USA.
Peng SL; Alpine Immune Sciences, Inc., Seattle, Washington, USA.; Pokaż więcej
Źródło:: Clinical and translational science [Clin Transl Sci] 2021 Jul; Vol. 14 (4), pp. 1314-1326. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: CD28 Antigens*/antagonists & inhibitors
CD28 Antigens*/metabolism
Immunosuppressive Agents*/administration & dosage
Immunosuppressive Agents*/adverse effects
Immunosuppressive Agents*/pharmacokinetics
Inducible T-Cell Co-Stimulator Protein*/antagonists & inhibitors
Inducible T-Cell Co-Stimulator Protein*/metabolism
Adolescent ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Administration, Intravenous ; Healthy Volunteers

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin (EU) in healthy adult males.
Autorzy:: Lickliter JD; Nucleus Network, Burnet Institute, Melbourne, Victoria, Australia.
Dadhania RN; Dr. Reddy's Laboratories. Ltd., Bachupally, Hyderabad, Telangana, India.
Trivedi RK; Dr. Reddy's Laboratories. Ltd., Bachupally, Hyderabad, Telangana, India.
Naveen Kumar SR; Dr. Reddy's Laboratories. Ltd., Bachupally, Hyderabad, Telangana, India.
Reddy PK; Dr. Reddy's Laboratories. Ltd., Bachupally, Hyderabad, Telangana, India.; Pokaż więcej
Źródło:: The Indian journal of medical research [Indian J Med Res] 2021 Mar; Vol. 154 (3), pp. 509-519.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:: Biosimilar Pharmaceuticals*/adverse effects
Trastuzumab*/adverse effects
Trastuzumab*/pharmacokinetics
Adolescent ; Adult ; Antibodies, Monoclonal, Humanized ; Area Under Curve ; Breast Neoplasms/drug therapy ; Double-Blind Method ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Therapeutic Equivalency ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Autorzy:: Forster AH; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.
Witham K; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.
Depelsenaire ACI; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.
Veitch M; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, TRI, Brisbane, Queensland, Australia.
Wells JW; The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, TRI, Brisbane, Queensland, Australia.
Wheatley A; Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Pryor M; 360biolabs, Melbourne, Victoria, Australia.
Lickliter JD; Nucleus Network Pty Ltd, Melbourne, Victoria, Australia.
Francis B; Avance Clinical Pty Ltd, Thebarton, South Australia, Australia.
Rockman S; Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Seqirus Pty Ltd, Parkville, Victoria, Australia.
Bodle J; Seqirus Pty Ltd, Parkville, Victoria, Australia.
Treasure P; Peter Treasure Statistical Services Ltd, Kings Lynn, United Kingdom.
Hickling J; Working in Tandem Ltd, Cambridge, United Kingdom.
Fernando GJP; Vaxxas Pty Ltd, Brisbane, Queensland, Australia.; The University of Queensland, School of Chemistry & Molecular Biosciences, Faculty of Science, Brisbane, Queensland, Australia.; Pokaż więcej
Źródło:: PLoS medicine [PLoS Med] 2020 Mar 17; Vol. 17 (3), pp. e1003024. Date of Electronic Publication: 2020 Mar 17 (Print Publication: 2020).
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Immunogenicity, Vaccine*
Vaccination*/adverse effects
Influenza A Virus, H1N1 Subtype/*immunology
Influenza Vaccines/*administration & dosage
Influenza, Human/*prevention & control
Administration, Cutaneous ; Adolescent ; Adult ; Antibodies, Viral/blood ; Australia ; Cells, Cultured ; Drug Stability ; Female ; Humans ; Immunoglobulin A/metabolism ; Influenza Vaccines/adverse effects ; Influenza, Human/immunology ; Influenza, Human/virology ; Injections, Intramuscular ; Male ; Saliva/immunology ; Saliva/virology ; T-Lymphocytes/immunology ; T-Lymphocytes/virology ; Time Factors ; Transdermal Patch ; Treatment Outcome ; Young Adult